FDA approves gene therapy for Sanfilippo syndrome type A

The FDA approved a gene therapy for Sanfilippo syndrome type A, an ultra-rare pediatric neurodegenerative disease. This marks a first regulatory approval for this condition, though long-term efficacy and durability remain unproven. The decision sets a precedent for gene therapy in ultra-rare diseases and may influence pricing and reimbursement debates.